Ka. Schleman et al., Predicting response to carvedilol for the treatment of heart failure: A multivariate retrospective analysis, J CARD FAIL, 7(1), 2001, pp. 4-12
Background: Carvedilol has been shown to decrease the progression of heart
failure and improve left ventricular function and survival in patients with
a left ventricular ejection fraction (LVEF) less than 35%, However, not al
l patients respond uniformly to this therapy. We proposed to identify varia
bles that could, potentially, be used to predict response to carvedilol the
rapy as measured by the change in LVEF after treatment (Delta LVEF), and to
identify pretreatment variables associated with hospitalization for heart
failure after carvedilol therapy.
Methods and Results: A retrospective analysis of 98 patients treated with o
pen-label carvedilol for a mean period of 16 months was performed by using
bivariate and step-wise multivariate analyses. Bivariate analysis showed a
positive correlation of Delta LVEF with heart rate at baseline (P = .001).
There was a negative correlation of Delta LVEF with baseline LVEF (P < .01)
, diabetes mellitus (P = .04), and ischemic cardiomyopathy (P = .0002). Mul
tivariate analysis showed a positive correlation of <Delta>LVEF with heart
rate at baseline (P = .01) and a negative correlation with initial LVEF (P
= .02) and ischemic cardiomyopathy (P = .006). Variables associated with ho
spitalization after initiation of carvedilol therapy were New York Heart As
sociation (NYHA) classification (P = .001), lower extremity edema (P = .001
), presence of an S3 (P = .02), hyponatremia (P = .02). elevated blood urea
nitrogen (BUN) (P = .002), atrial fibrillation (P = .001), diabetes mellit
us (P = .02), and obstructive sleep apnea (P = .009).
Conclusions: Heart failure patients with the lowest LVEF or the highest hea
rt rate at baseline had the greatest gain in LVEF after treatment with carv
edilol. Patients with ischemic cardiomyopathy derived less benefit. Patient
s with clinical evidence of decompensated heart failure were at greater ris
k for hospitalization after initiation of carvedilol therapy.